IRX-101 added to eye injections for safety testing
Part of Eyes & vision clinical trials.
This Phase 3 study tests whether IRX-101 is safe and well-tolerated in people receiving anti-VEGF injections directly into the eye. It may help doctors find a safer way to pair this study treatment with standard eye injection care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can give informed consent (understand and agree to join)
- You are willing and able to follow the study plan for the full study period
- You are age 18 or older and get anti-VEGF injections into one or both eyes
- You do not have a history of endophthalmitis (a serious eye infection)
- You do not currently have uveitis (inflammation inside the eye)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This trial tests a new cell therapy called TRX103 for people with active uveitis not caused by an infection. It aims to see if the treatment is safe and helps reduce eye inflammation.
This trial studies whether LX103 can improve vision and is safe for people with X-linked retinoschisis (XLRS) caused by RS1 gene changes. It focuses on a specific level of vision in the study eye and checks for medical conditions that could affect eye testing or safety.
This trial tests a single injection of a new medicine, RTx-021, into the eye for people with Stargardt disease. The goal is to see if it is safe and to find the right dose.
This trial tests an eye injection called KIO-104 to treat macular edema (swelling in the center of the retina) caused by conditions like uveitis, diabetes, or vein blockage. The goal is to see if it is safe and improves vision.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
Hear when a new Retinal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.